India to Hungary: Gliclazide Export Trade Route

The India to Hungary Gliclazide corridor is one of India's established pharmaceutical export routes, with 47 shipments documented worth a combined $88.2M USD. The route is dominated by MYLAN LABORATORIES LIMITED, which alone accounts for roughly 100% of all export value, reflecting the consolidated nature of India's gliclazide manufacturing sector.

Across 4 active suppliers, the average shipment value stands at $1.9M USD — a figure that reflects both bulk commercial orders from large pharmaceutical companies and smaller specialty shipments. Sea freight dominates at 74% of all shipments, consistent with gliclazide's non-urgent bulk-order profile.

Shipment activity peaks during April–June, with an average transit time of 33 days port-to-port. The route has recorded an annual growth rate of 21.7%, placing it at rank #5 among India's top gliclazide export destinations globally.

On the import side, key buyers of Indian gliclazide in Hungary include MYLAN HUNGARY KFT,, MYLAN HUNGARY KFT, MYLAN HUNGARY KFT MYLAN U and 6 others. MYLAN HUNGARY KFT, is the single largest importer with 19 shipments valued at $86.9M USD.

India's gliclazide exports to Hungary are driven primarily by a handful of large-scale manufacturers. MYLAN LABORATORIES LIMITED with 41 shipments leads the pack, a pattern common in generic pharmaceutical corridors where manufacturing scale creates significant cost advantages. The presence of 4 active exporters signals a competitive but concentrated market — buyers in Hungary benefit from supplier diversity while the top tier handles the majority of volume.

The top 3 suppliers — MYLAN LABORATORIES LIMITED, MYLAN LABORATORIES LIMITED , LAUREL PHARMA LABS — together account for 100% of total trade value on this route. The average shipment value of $1.9M USD reflects primarily bulk commercial orders from large pharmaceutical distributors.

Beyond the primary product category, shipments on this route include closely related formulations such as gliclazide modified release tablets 30 mg (packs 5000s bsp) and gliclazide modified release tablets 30 m, suggesting that buyers in Hungary tend to consolidate orders across related product lines from the same Indian supplier.

On the buying side, MYLAN HUNGARY KFT, is the largest importer with 19 shipments worth $86.9M USD — representing 99% of all gliclazide imports from India on this route. A total of 9 buyers are active on this corridor.